Premier Perspectives The blog for insider insights in clinical development Clinical Research: Phase 1 - Phase 4 Patient-Centered Hematological Malignancy Trials: A Blueprint for Success By Ashley Herrick December 5, 2023 Featured Posts Consulting CMC Considerations for Pre-IND Meetings By Ryan Key November 29, 2023 Clinical ResearchPhase 1 - Phase 4 8 Cost Containment Strategies for Rare Disease Clinical Trials By Leslie Wetherell November 21, 2023 Premier Voices Podcast Conversations with Premier's subject matter experts PREMIER VOICES #15 Enhancing Clinical Trial Accessibility – Bringing Oncology Trials to Patients PREMIER VOICES #13 Early-Phase Oncology – Emerging From the Crisis & Innovating for the Future PREMIER VOICES #12 Direct-to-Patient – Is This the ‘New Normal’ for Clinical Trials? PREMIER VOICES #11 Statistical Considerations in the Wake of COVID-19 PREMIER VOICES #10 COVID-19 Update – How the FDA's Emergency Use Authorization Can Help Develop Therapies Faster Premier Voices #8 Engaging Patients in Clinical Trials w/ Alan Thomas Premier Voices #7 Rare Disease Advocacy & International Ataxia Day w/ Alan Thomas (Ataxia & Me) Premier Voices #6 Operationalizing the New MDR With Janet Kube (Part 2) Premier Voices #5 Operationalizing the New MDR With Janet Kube (Part 1) Premier Voices #4 The Placebo Problem Part 2 With Michael Kuss Recent Posts By expertise area All expertise areas Medical DeviceRare DiseaseOncology & HematologyDiagnosticsDigital TherapeuticsMedTechPediatricsNeuroscienceAnalgesiaDermatologyOtherCOVID-19Cell & Gene TherapyWomen's HealthReal-World & Late PhaseCareers By functional area All functional areas Development StrategyClinical Research: Phase 1 - Phase 4ConsultingData Management & BiostatisticsFunctional Service Provider (FSP)Global ComplianceMedical and Regulatory AffairsPatient and Stakeholder EngagementProject ManagementQualityReal-World Science and Late PhaseSafety/PharmacovigilanceStudy DesignStudy Start-UpOtherCOVID-19Product Development Clinical ResearchPhase 1 - Phase 4 5 Stepping Stones to the Future State of Rare Disease Clinical Development By Leslie Wetherell November 14, 2023 Clinical ResearchPhase 1 - Phase 4 Getting It Right from the Start: 10 Essentials for Designing Biomarker-Guided Oncology Clinical Studies By Rupa Doshi October 20, 2023 Clinical ResearchPhase 1 - Phase 4 Navigating the FDA’s Draft Guidance on Psychedelic Drug Development By Adam Simmons October 18, 2023 Clinical ResearchPhase 1 - Phase 4 Operationalizing Biomarker-Guided Oncology Trials: Planning for Success By Rupa Doshi October 17, 2023 Clinical ResearchPhase 1 - Phase 4 Leveraging Technology and Expert Clinician Review to Enhance Risk Detection in Neuroscience Studies By Andreas Schreiner October 16, 2023 Clinical ResearchPhase 1 - Phase 4 What Patient Population is Participating in Your Early-Phase Gene Therapy Trials? These Factors Could Influence Your Strategy By Kenneth Ndugga-Kabuye September 6, 2023 1 2 3 … 53 Next × ALSO OF INTEREST7 Questions About Clinical Evaluations for MDRNostalgia or Shell Shock? Assessing PTSD Is a...Designing Pediatric Analgesic Treatment...